Advances of Berberine Against Metabolic Syndrome-associated Kidney Disease: Regarding Effect and Mechanism

Overview

Journal Front Pharmacol

Date 2023 Feb 23

PMID 36814494

Authors

Ya-Fei Liu

Huan-Huan Wang

Yin-Hong Geng

Liang Han

Sheng-Hao Tu

Hui Wang

Affiliations

Soon will be listed here.

Abstract

The prevalence of metabolic syndrome (MetS) is drastically growing worldwide, resulting in MetS-associated kidney disease. According to traditional theories, preventing blood pressure, lipid, glycose, and obesity and improving insulin resistance (IR), a couple of medications are required for MetS. It not only lowers patients' compliance but also elevates adverse reactions. Accordingly, we attempted to seek answers from complementary and alternative medicine. Ultimately, berberine (BBR) was chosen due to its efficacy and safety on MetS through multi-pathways and multi-targets. The effects and mechanisms of BBR on obesity, IR, diabetic nephropathy, hypertension, hyperlipidemia, and hyperuricemia were elaborated. In addition, the overall properties of BBR and interventions for various kidney diseases were also collected. However, more clinical trials are expected to further identify the beneficial effects of BBR.

Citing Articles

The link between hyperuricemia and diabetes: insights from a quantitative analysis of scientific literature.

Ma L, Wang J, Ma L, Wang X Front Endocrinol (Lausanne). 2025; 15:1441503.

PMID: 39991045 PMC: 11842261. DOI: 10.3389/fendo.2024.1441503.

Metabolic Syndrome, Kidney-Related Adiposity, and Kidney Microcirculation: Unraveling the Damage.

Jang K, Hur J, Lee D, Kim S Biomedicines. 2025; 12(12.

PMID: 39767613 PMC: 11673429. DOI: 10.3390/biomedicines12122706.

Advances in the study of key cells and signaling pathways in renal fibrosis and the interventional role of Chinese medicines.

Liang L, Mi Y, Zhou S, Yang A, Wei C, Dai E Front Pharmacol. 2024; 15:1403227.

PMID: 39687302 PMC: 11647084. DOI: 10.3389/fphar.2024.1403227.

Development, validation and economic evaluation of a machine learning algorithm for predicting the probability of kidney damage in patients with hyperuricaemia: protocol for a retrospective study.

Hou Z, Yang Y, Deng B, Gao G, Li M, Liu X BMJ Open. 2024; 14(11):e086032.

PMID: 39613447 PMC: 11605815. DOI: 10.1136/bmjopen-2024-086032.

Preparation and Evaluation of Berberine-Excipient Complexes in Enhancing the Dissolution Rate of Berberine Incorporated into Pellet Formulations.

Abbaspour M, Faeznia F, Zanjanian P, Ruzbehi M, Shourgashti K, Ziaee A AAPS PharmSciTech. 2024; 25(6):154.

PMID: 38961012 DOI: 10.1208/s12249-024-02863-1.

References

Ma Z, Zhu L, Wang S, Guo X, Sun B, Wang Q . Berberine protects diabetic nephropathy by suppressing epithelial-to-mesenchymal transition involving the inactivation of the NLRP3 inflammasome. Ren Fail. 2022; 44(1):923-932. PMC: 9154812. DOI: 10.1080/0886022X.2022.2079525. View

Cao C, Su M . Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Exp Ther Med. 2019; 17(4):3009-3014. PMC: 6434235. DOI: 10.3892/etm.2019.7295. View

Wang H, Zhang H, Gao Z, Zhang Q, Gu C . The mechanism of berberine alleviating metabolic disorder based on gut microbiome. Front Cell Infect Microbiol. 2022; 12:854885. PMC: 9452888. DOI: 10.3389/fcimb.2022.854885. View

Yue S, Liu J, Wang A, Meng X, Yang Z, Peng C . Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids. Am J Physiol Endocrinol Metab. 2018; 316(1):E73-E85. DOI: 10.1152/ajpendo.00256.2018. View

Hua W, Ding L, Chen Y, Gong B, He J, Xu G . Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal. 2007; 44(4):931-7. DOI: 10.1016/j.jpba.2007.03.022. View

Liu X, Li G, Zhu H, Huang L, Liu Y, Ma C . Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. Endocr J. 2010; 57(10):881-93. DOI: 10.1507/endocrj.k10e-043. View

Wang Z, Wu F, Zhou Q, Qiu Y, Zhang J, Tu Q . Berberine Improves Vascular Dysfunction by Inhibiting Trimethylamine-N-oxide Regulating the Gut Microbiota in Angiotensin II-Induced Hypertensive Mice. Front Microbiol. 2022; 13:814855. PMC: 8957906. DOI: 10.3389/fmicb.2022.814855. View

Saklayen M . The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018; 20(2):12. PMC: 5866840. DOI: 10.1007/s11906-018-0812-z. View

Ni W, Ding H, Zhou H, Qiu Y, Tang L . Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats. Eur J Pharmacol. 2015; 764:448-456. DOI: 10.1016/j.ejphar.2015.07.040. View

10.

Cai Y, Xin Q, Lu J, Miao Y, Lin Q, Cong W . A New Therapeutic Candidate for Cardiovascular Diseases: Berberine. Front Pharmacol. 2021; 12:631100. PMC: 8010184. DOI: 10.3389/fphar.2021.631100. View

11.

Sun D, Wang J, Shao W, Wang J, Yao L, Li Z . Pathogenesis and Damage Targets of Hypertensive Kidney Injury. J Transl Int Med. 2021; 8(4):205-209. PMC: 7805285. DOI: 10.2478/jtim-2020-0033. View

12.

Dai J, Huang X, Zhang C, Gao J . Mechanisms of lipid metabolism promoted by berberine via peroxisome proliferator-activated receptor gamma during in vitro maturation of porcine oocytes. Anim Sci J. 2021; 92(1):e13582. DOI: 10.1111/asj.13582. View

13.

Shen J, Wang W, Shao X, Wu J, Li S, Che X . Integrated Analysis of m6A Methylome in Cisplatin-Induced Acute Kidney Injury and Berberine Alleviation in Mouse. Front Genet. 2020; 11:584460. PMC: 7718005. DOI: 10.3389/fgene.2020.584460. View

14.

Shou J, Li X, Tang Y, Kong B, Wu H, Xiao M . Novel mechanistic insight on the neuroprotective effect of berberine: The role of PPARδ for antioxidant action. Free Radic Biol Med. 2022; 181:62-71. DOI: 10.1016/j.freeradbiomed.2022.01.022. View

15.

Ren G, Guo J, Qian Y, Kong W, Jiang J . Berberine Improves Glucose and Lipid Metabolism in HepG2 Cells Through AMPKα1 Activation. Front Pharmacol. 2020; 11:647. PMC: 7225256. DOI: 10.3389/fphar.2020.00647. View

16.

Dong Z, Lin H, Chen F, Che X, Bi W, Shi S . Berberine improves intralipid-induced insulin resistance in murine. Acta Pharmacol Sin. 2020; 42(5):735-743. PMC: 8115075. DOI: 10.1038/s41401-020-0493-4. View

17.

Zhang M, Zhang Y, Xiao D, Zhang J, Wang X, Guan F . Highly bioavailable berberine formulation ameliorates diabetic nephropathy through the inhibition of glomerular mesangial matrix expansion and the activation of autophagy. Eur J Pharmacol. 2020; 873:172955. DOI: 10.1016/j.ejphar.2020.172955. View

18.

Sun S, Yang Y, Xiong R, Ni Y, Ma X, Hou M . Oral berberine ameliorates high-fat diet-induced obesity by activating TAS2Rs in tuft and endocrine cells in the gut. Life Sci. 2022; 311(Pt A):121141. DOI: 10.1016/j.lfs.2022.121141. View

19.

Ding B, Geng S, Hou X, Ma X, Xu H, Yang F . Berberine Reduces Renal Cell Pyroptosis in Golden Hamsters with Diabetic Nephropathy through the Nrf2-NLRP3-Caspase-1-GSDMD Pathway. Evid Based Complement Alternat Med. 2022; 2021:5545193. PMC: 9375700. DOI: 10.1155/2021/5545193. View

20.

Fouad G, Ahmed K . The protective impact of berberine against doxorubicin-induced nephrotoxicity in rats. Tissue Cell. 2021; 73:101612. DOI: 10.1016/j.tice.2021.101612. View